CRBN、MUM1、C-MYC、BCL-2在弥漫性大B细胞淋巴瘤中的表达及与来那度胺疗效的关系  

Relationship between the expressions of CRBN,MUM1,C-MYC,BCL-2 in diffuse large B-cell lymphoma and the efficacy of lenalidomide

作　　者：王丽萍 冯江龙 李品浩 吴涛 黄玉鑫 杨文秀[1,2] WANG Liping;FENG Jianglong;LI Pinhao;WU Tao;HUANG Yuxin;YANG Wenxiu(Department of Pathology,Guizhou Medical University,Guizhou Guiyang 550004,China;Pathology Department,the Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China;Lymphoma Department,the Affiliated Tumor Hospital of Guizhou Medical University,Guizhou Guiyang 550008,China)

机构地区：[1]贵州医科大学病理学教研室,贵州贵阳550004 [2]贵州医科大学附属医院病理科,贵州贵阳550004 [3]贵州医科大学附属肿瘤医院淋巴瘤科,贵州贵阳550008

出　　处：《现代肿瘤医学》2022年第24期4490-4495,共6页Journal of Modern Oncology

基　　金：贵州省科技计划项目经费资助(编号:黔科合支撑[2020]4Y147号)。

摘　　要：目的:探讨CRBN、MUM1、C-MYC、BCL-2在DLBCL中的表达及与来那度胺疗效的关系,为来那度胺疗效预测评估提供一定的依据。方法:收集DLBCL予来那度胺+R-CHOP治疗的57例作为治疗组,单用R-CHOP的39例作为对照组。治疗3个周期后复查影像学将CR+PR视为有效组,SD+PD视为无效组;免疫组化染色检测CRBN、MUM1、C-MYC、BCL-2的蛋白表达,RT-qPCR检测CRBN mRNA表达量,进行统计分析。结果:CRBN mRNA表达水平在来那度胺有效组和无效组之间具有统计学差异(P=0.0332)。CRBN、MUM1、C-MYC蛋白表达水平在来那度胺有效组和无效组之间具有统计学差异(P分别为0.0001,0.0306,0.0257);两组之间BCL-2蛋白表达无统计学差异(P=0.3910)。生存分析:来那度胺治疗组和对照组病例之间生存预后差异明显(P=0.028)。结论:来那度胺能有效延长DLBCL患者生存预后时间;CRBN、MUM1、C-MYC高表达患者能够从来那度胺治疗中获益,CRBN、MUM1、C-MYC可能是来那度胺治疗DLBCL的疗效预测指标。Objective:To investigate the relationship between the expressions of CRBN,MUM1,C-MYC,and BCL-2 in DLBCL and the efficacy of lenalidomide,providing a certain basis for the prediction and evaluation of lenalidomide efficacy.Methods:57 DLBCL patients treated with lenalidomide+R-CHOP were enrolled as the treatment group,and 39 patients treated with R-CHOP alone were enrolled as the control group.After 3 cycles of treatment,CR+PR was regarded as effective group and SD+PD as invalid group.The protein expressions of CRBN,MUM1,C-MYC,and BCL-2 were detected by immunohistochemical staining.The mRNA expression levels of CRBN were detected by RT-qPCR.We performed statistical analysis.Results:The CRBN mRNA expression levels were significantly different between the lenalidomide effective group and the invalid group(P=0.0332).The protein expression levels of CRBN,MUM1,and C-MYC were significantly different between the lenalidomide effective and invalid groups(P=0.0001,0.0306 and 0.0257,respectively).There were no significant difference in BCL-2 protein expressions between the two groups(P=0.3910).Survival analysis:There were significant difference in survival prognosis between the lenalidomide treatment group and the control group(P=0.028).Conclusion:Lenalidomide can effectively prolong the survival and prognosis time of DLBCL patients.Patients with high expression of CRBN,MUM1,and C-MYC could benefit from lenalidomide treatment.CRBN,MUM1,and C-MYC may be forecast indexes of lenalidomide efficacy in DLBCL.

关 键 词：来那度胺 弥漫性大B细胞淋巴瘤 羟脑苷脂 多发性骨髓瘤癌基因-1 人髓细胞增生原癌基因 B淋巴细胞瘤2基因 

分 类 号：R733.4[医药卫生—肿瘤]